? Integrative Bioinformatics Core Precision medicine is an emerging integrative approach for disease prevention, early detection and treatment that takes into account individual variability in genetics, medical history, environmental exposures, and lifestyle. The development and availability of genomic and other molecular profiling technologies in combination with the deployment of electronic health records (EHR) provide an unprecedented opportunity to apply precision medicine strategies in rheumatic disease research. The overall goal of the Integrative Bioinformatics (IB) Core is to provide researchers with access to state-of-the-art computational approaches for the study of rheumatic disorders. Directed by leading experts in computational biology and bioinformatics, the IB Core will provide investigators with assistance in study design, bioinformatics data analysis, data integration and data dissemination. To advance rheumatic disease research in the context of precision medicine, the IB Core will provide project consultation, education, and outreach for the Center community, as well as the analysis and integration of high quality genomics, molecular and clinical data. In collaboration with the Genomics and Molecular Resources (GMR) and Human Subjects and Clinical Phenotyping (HSCP) Cores, the IB Core will assist researchers with bioinformatics analysis to advance precision medicine in rheumatology. With those goals in mind we propose the following aims.
In Aim 1, we will provide analytical consulting services in study design, data analysis and data integration with public datasets in order to advance precision medicine in rheumatic disease research.
In Aim 2, the IB Core will develop novel tools, software and analytical pipelines for the integration, annotation, analysis, retrieval, and presentation of data from clinical and molecular studies of rheumatic diseases. As a result of this Aim, we will furthermore establish and maintain a technologically up- to-date toolset that can be readily used for systems-level analyses of the data.
Aim 3 is to integrate molecular and clinical data and leverage collaborations between the GMR and HSCP Cores and facilitate integrative computational analysis for a wide range of clinical, translational and basic research studies to enable precision medicine in rheumatology. Finally, in Aim 4, we will provide centralized data management and storage including assistance in dissemination of data for P30 associated projects using the Immunology Database and Analysis Portal (ImmPort). The IB Core will bring together researchers from different backgrounds and enable investigators whose work can benefit from access to state-of-the-art computational technologies and approaches, with an overall goal of advancing precision medicine in rheumatology.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Center Core Grants (P30)
Project #
5P30AR070155-04
Application #
9768177
Study Section
Special Emphasis Panel (ZAR1)
Project Start
Project End
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
4
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118
Kang, Hyun Min; Subramaniam, Meena; Targ, Sasha et al. (2018) Multiplexed droplet single-cell RNA-sequencing using natural genetic variation. Nat Biotechnol 36:89-94
Kosti, Idit; Sirota, Marina (2018) Electronic Medical Records Enable Precision Medicine Approaches for Celiac Disease. J Pediatr Gastroenterol Nutr 67:434-435
Ragouzeos, Dana; Gandrup, Julie; Berrean, Beth et al. (2018) ""Am I OK?"" using human centered design to empower rheumatoid arthritis patients through patient reported outcomes. Patient Educ Couns :
Schmajuk, Gabriela; Jafri, Kashif; Evans, Michael et al. (2018) Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs. Semin Arthritis Rheum :
Yazdany, Jinoos; Dudley, R Adams; Lin, Grace A et al. (2018) Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D. JAMA 320:931-933
Izadi, Zara; Gandrup, Julie; Katz, Patricia P et al. (2018) Patient-reported outcome measures for use in clinical trials of SLE: a review. Lupus Sci Med 5:e000279
Barruet, Emilie; Morales, Blanca M; Cain, Corey J et al. (2018) NF-?B/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification. JCI Insight 3:
Sciascia, Savino; Yazdany, Jinoos; Dall'Era, Maria et al. (2018) Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study. Ann Rheum Dis :
Lanata, Cristina M; Chung, Sharon A; Criswell, Lindsey A (2018) DNA methylation 101: what is important to know about DNA methylation and its role in SLE risk and disease heterogeneity. Lupus Sci Med 5:e000285
Apeltsin, Leonard; Wang, Shengzhi; von Büdingen, H-Christian et al. (2017) A Haystack Heuristic for Autoimmune Disease Biomarker Discovery Using Next-Gen Immune Repertoire Sequencing Data. Sci Rep 7:5338

Showing the most recent 10 out of 13 publications